Group 1 - The company achieved revenue of 270 million yuan in the first half of 2025, representing a year-on-year growth of 20.10%, and a net profit attributable to shareholders of 75.88 million yuan, up 15.31% year-on-year [1] - In Q2 2025, the company reported revenue of 135 million yuan, a year-on-year increase of 0.94%, with a net profit of 41.09 million yuan, growing 14.19% year-on-year [1] - The demand for peptide drugs, particularly GLP-1 drugs like semaglutide and tirzepatide, is rapidly increasing, contributing to the company's performance [1] Group 2 - The company has established long-term stable partnerships with over 1,900 pharmaceutical R&D and production enterprises globally, including major players like Bachem AG and Lonza AG [2] - A wholly-owned subsidiary, Highfine Biotech GmbH, was established in Germany in January 2025 to enhance connections and services for European clients [2] - The company is expanding its production capacity through self-built facilities and acquisitions, with significant projects underway to alleviate supply bottlenecks [2]